Akron Bio, a provider of critical inputs for cell and gene therapies, has announced the appointment of Christopher Murphy as Chief Executive Officer (CEO).
A biotechnology industry veteran, Murphy has more than 30 years of experience in advanced therapy and biological drug development and manufacturing.
Most recently, Murphy served as Vice President and General Manager of Viral Vector Services at Thermo Fisher Scientific.
Murphy joined Thermo Fisher Scientific as part of its acquisition of Brammer Bio, where he served as CEO.
He previously held leadership roles at Sanofi Genzyme, BioReliance, and Lederle Laboratories (now Pfizer).
Arcline Investment Management commented:
“Chris brings an exceptional track record of building and growing businesses that address critical demands in the rapidly developing cell and gene therapy industry.
“We are thrilled to welcome Chris as Akron’s CEO and believe his passion and expertise will be invaluable in strengthening the company’s position as a leading supplier to cell and gene therapy companies.”
Akron Bio is a materials manufacturer and services provider to the regenerative medicine industry.
The company provides advanced therapy developers the scale, compliance and regulatory support necessary to drive novel treatments from discovery to commercialisation
“I am incredibly excited to join Akron Bio and partner with innovators to provide high-quality, critical materials and services that power the future of medicine.
“Our differentiated products, expertise, and agility are crucial in this rapidly evolving advanced therapy industry.
“I look forward to working with this exceptional team to enable customers to realise the potential of these medicines for people in need.”
Healthcare innovators and leaders honoured at Imprivata HealthCon user group and awards ceremony
Wearable communication system may reduce digital health divide
Molecule trains the immune system to prevent cancer
Diabetes patients urged to use fitness games with caution
Urgent work needed to tackle ‘substantial’ digital health inequality
eSight: “The technology has the potential to change someone’s life”
Microsoft invests £2.5 billion in UK AI
TMS shows promise in tackling depression ‘epidemic’
AI depression app set for NHS clinical trial
UK Biobank releases world’s largest single set of sequencing data
- News3 weeks ago
Why a leading healthcare CEO sees recombinant DNA as a metaphor for developing breakthrough technologies
- AI6 days ago
AI model predicts breast cancer risk without racial bias
- Medtech4 weeks ago
Surtex Instruments to unveil game-changing Infinex microsurgery instruments at MEDICA
- AI2 weeks ago
Humans make better cancer treatment decisions than AI, study finds